AR099971A1 - UNIT DOSE FORM THAT INCLUDES EMTRICITABINE, TENOFOVIR, DARUNAVIR AND RITONAVIR AND A MONOLITICAL TABLET THAT INCLUDES DARUNAVIR AND RITONAVIR - Google Patents

UNIT DOSE FORM THAT INCLUDES EMTRICITABINE, TENOFOVIR, DARUNAVIR AND RITONAVIR AND A MONOLITICAL TABLET THAT INCLUDES DARUNAVIR AND RITONAVIR

Info

Publication number
AR099971A1
AR099971A1 ARP150101041A ARP150101041A AR099971A1 AR 099971 A1 AR099971 A1 AR 099971A1 AR P150101041 A ARP150101041 A AR P150101041A AR P150101041 A ARP150101041 A AR P150101041A AR 099971 A1 AR099971 A1 AR 099971A1
Authority
AR
Argentina
Prior art keywords
ritonavir
darunavir
tenofovir
emtricitabine
granulate
Prior art date
Application number
ARP150101041A
Other languages
Spanish (es)
Inventor
Shahar Nitzan
Haronsky Elina
Hrakovsky Julia
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of AR099971A1 publication Critical patent/AR099971A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Forma de dosificación oral que comprende Emtricitabina, Tenofovir, Darunavir y Ritonavir y un comprimido monolítico que comprende Darunavir y Ritonavir y su uso para tratar infección por HIV. Reivindicación 23: Una formulación farmacéutica de acuerdo con cualquiera de las reivindicaciones precedentes caracterizada porque la forma de dosificación unitaria comprende: (a) aproximadamente 300 mg de tenofovir disoproxil fumarato, (b) aproximadamente 200 mg de emtricitabina, (c) aproximadamente 800 mg de darunavir y (d) menor o igual a aproximadamente 70 mg de ritonavir. Reivindicación 26: Una formulación farmacéutica de acuerdo con la reivindicación 25 caracterizada porque la capa simple comprende: (a) una mezcla de: (i) un granulado de darunavir con ritonavir extragranular o un granulado de darunavir con ritonavir intragranular, (es decir un granulado de darunavir-ritonavir), (ii) gránulos de emtricitabina, y (iii) gránulos de tenofovir (preferentemente tenofovir disoproxilo, y más preferentemente tenofovir disoproxil fumarato), (b) una mezcla de (i) un granulado de darunavir con ritonavir extragranular o un granulado de darunavir con ritonavir intragranular, (es decir un granulado de darunavir ritonavir), con (ii) gránulos que comprenden emtricitabina y tenofovir; o (c) una mezcla de: (i) un granulado de darunavir y (ii) gránulos que comprenden emtricitabina, tenofovir y ritonavir.Oral dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir and a monolithic tablet comprising Darunavir and Ritonavir and its use to treat HIV infection. Claim 23: A pharmaceutical formulation according to any of the preceding claims characterized in that the unit dosage form comprises: (a) approximately 300 mg of tenofovir disoproxil fumarate, (b) approximately 200 mg of emtricitabine, (c) approximately 800 mg of darunavir and (d) less than or equal to approximately 70 mg ritonavir. Claim 26: A pharmaceutical formulation according to claim 25 characterized in that the single layer comprises: (a) a mixture of: (i) a granulate of darunavir with extragranular ritonavir or a granulate of darunavir with intragranular ritonavir, (i.e. a granulate of darunavir-ritonavir), (ii) granules of emtricitabine, and (iii) granules of tenofovir (preferably tenofovir disoproxil, and more preferably tenofovir disoproxil fumarate), (b) a mixture of (i) a granulate of darunavir with extragranular ritonavir or a granulate of darunavir with intragranular ritonavir, (ie a granulate of darunavir ritonavir), with (ii) granules comprising emtricitabine and tenofovir; or (c) a mixture of: (i) a darunavir granulate and (ii) granules comprising emtricitabine, tenofovir and ritonavir.

ARP150101041A 2014-04-08 2015-04-07 UNIT DOSE FORM THAT INCLUDES EMTRICITABINE, TENOFOVIR, DARUNAVIR AND RITONAVIR AND A MONOLITICAL TABLET THAT INCLUDES DARUNAVIR AND RITONAVIR AR099971A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461976917P 2014-04-08 2014-04-08

Publications (1)

Publication Number Publication Date
AR099971A1 true AR099971A1 (en) 2016-08-31

Family

ID=58699992

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101041A AR099971A1 (en) 2014-04-08 2015-04-07 UNIT DOSE FORM THAT INCLUDES EMTRICITABINE, TENOFOVIR, DARUNAVIR AND RITONAVIR AND A MONOLITICAL TABLET THAT INCLUDES DARUNAVIR AND RITONAVIR

Country Status (1)

Country Link
AR (1) AR099971A1 (en)

Similar Documents

Publication Publication Date Title
ECSP17084331A (en) PHARMACEUTICAL FORMULATIONS
CY1124052T1 (en) ORALLY DISPERSIBLE TABLET CONTAINING ESTETROL
EA201792591A1 (en) PHARMACEUTICAL PREPARATIONS
ECSP16084317A (en) PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE
IL280083A (en) Pharmaceutical dosage form which can be administered orally and has modified release
WO2015028875A3 (en) Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
ECSP16086232A (en) (R) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
PE20160245A1 (en) STABLE ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION IN A FORM OF A DISPERSABLE TABLET INCLUDING ISONIAZID GRANULES AND RIFAPENTINE GRANULES AND THEIR PREPARATION PROCESS
AR110374A1 (en) DOSED FORMS OF MODIFIED GASTRORETENTIVE RELEASE FOR OPROZOMIB AND PROCESS FOR MANUFACTURING
ECSP16005208A (en) STABLE ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET INCLUDING ISONIAZID GRANULES AND RIFAPENTINE GRANULES AND THEIR PREPARATION PROCESS
AR099971A1 (en) UNIT DOSE FORM THAT INCLUDES EMTRICITABINE, TENOFOVIR, DARUNAVIR AND RITONAVIR AND A MONOLITICAL TABLET THAT INCLUDES DARUNAVIR AND RITONAVIR
MX2017013643A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix.
CO2018010142A2 (en) Mesalazine solid formula preparation process
CY1120749T1 (en) PHARMACEUTICAL DOSAGE FORMS
UY37413A (en) OPROZOMIB IMMEDIATE RELEASE FORMULATIONS
PH12020550456A1 (en) Alcohol-resistant oral pharmaceutical compositions of lorazepam
CL2018002337A1 (en) Pharmaceutical composition to prevent and treat sleep disorders
UA97982U (en) DRESSING MEDICINE FOR TABLETS
CR20170601A (en) PHARMACEUTICAL FORMULATIONS THAT INCLUDE TENOFOVIR AND EMTRICITABINA
TR201722102A2 (en) A Pharmaceutical Product Containing Levodropropizine
UA120295U (en) ANTI-THROMBOCITARY ACTION MEDICINAL PRODUCT
CL2015003409A1 (en) Synergistic pharmaceutical composition of two analgesics with different pharmacokinetic profile
BR112018072583A2 (en) stable tablet tablet pharmaceutical composition
UA109242U (en) STABLE PHARMACEUTICAL COMPOSITION CONTAINING PROTEASOM INHIBITOR
CL2015003683A1 (en) Amorphous oral pharmaceutical formulation comprising the use of the formulation in the preparation of a medicament useful in the treatment and / or prophylaxis of diseases associated with the herpesviridae group, preferably associated with cytomegalovirus cmv amorphous letermovir preparation process.

Legal Events

Date Code Title Description
FB Suspension of granting procedure